BRIGHTPATH BIOTHERAPEUTICS CO., LTD. BrightPath Biotherapeutics Co., Ltd. Share Price
Equities
4594
JP3274140007
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59 JPY | 0.00% |
|
+5.36% | -32.18% |
| Sales 2017 | 529M 3.34M 267M | Sales 2018 | 354M 2.24M 179M | Capitalization | 33.68B 213M 17.03B |
|---|---|---|---|---|---|
| Net income 2017 | -1.11B -7.03M -563M | Net income 2018 | -1.58B -9.97M -797M | EV / Sales 2017 | 34.8 x |
| Net cash position 2017 | 4.95B 31.28M 2.5B | Net cash position 2018 | 6.53B 41.25M 3.3B | EV / Sales 2018 | 76.7 x |
| P/E ratio 2017 |
-19.2
x | P/E ratio 2018 |
-19.5
x | Employees | 42 |
| Yield 2017 * |
-
| Yield 2018 |
-
| Free-Float | 95.52% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +5.36% | ||
| Current month | -11.94% | ||
| 1 month | -7.81% | ||
| 3 months | -28.92% | ||
| 6 months | -47.79% | ||
| Current year | -32.18% |
1 week
56.00
61.00
1 month
56.0068.00
Current year
56.0099.00
1 year
56.00161.00
3 years
56.00270.00
5 years
56.00389.00
10 years
56.002 229.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kenichi Nagai
CEO | Chief Executive Officer | 53 | 31/12/08 |
| Director/Board Member | 55 | 30/04/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 77 | 31/05/15 | |
Akira Yamada
BRD | Director/Board Member | 67 | 30/04/03 |
Kenichi Nagai
CEO | Chief Executive Officer | 53 | 31/12/08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 59 | 0.00% | 69,000 |
| 25/04/24 | 59 | 0.00% | 87,800 |
| 24/04/24 | 59 | +1.72% | 249,500 |
| 23/04/24 | 58 | 0.00% | 248,700 |
| 22/04/24 | 58 | +3.57% | 273,700 |
Delayed Quote Japan Exchange, April 26, 2024 at 07:00 am
More quotes
BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.
Calendar
09/05/2024
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -32.18% | 26.51M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- 4594 Stock
